PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases
1
Université de Bordeaux, INSERM U1212, CNRS UMR 5320, ARNA, ARN: Régulations Naturelle et Artificielle, ChemBioPharm, 146 rue Léo Saignat, F-33076 Bordeaux, France
2
Univ. Bordeaux, CNRS, IMN, UMR 5293, F-33000 Bordeaux, France
*
Authors to whom correspondence should be addressed.
Academic Editor: Oya Tagit
Pharmaceutics 2021, 13(7), 1042; https://doi.org/10.3390/pharmaceutics13071042
Received: 3 June 2021
/
Revised: 5 July 2021
/
Accepted: 6 July 2021
/
Published: 8 July 2021
(This article belongs to the Special Issue Nanomedicine Formulations Based on PLGA Nanoparticles for Diagnosis, Monitoring and Treatment of Disease: From Bench to Bedside)
Treatment of neurodegenerative diseases has become one of the most challenging topics of the last decades due to their prevalence and increasing societal cost. The crucial point of the non-invasive therapeutic strategy for neurological disorder treatment relies on the drugs’ passage through the blood-brain barrier (BBB). Indeed, this biological barrier is involved in cerebral vascular homeostasis by its tight junctions, for example. One way to overcome this limit and deliver neuroprotective substances in the brain relies on nanotechnology-based approaches. Poly(lactic-co-glycolic acid) nanoparticles (PLGA NPs) are biocompatible, non-toxic, and provide many benefits, including improved drug solubility, protection against enzymatic digestion, increased targeting efficiency, and enhanced cellular internalization. This review will present an overview of the latest findings and advances in the PLGA NP-based approach for neuroprotective drug delivery in the case of neurodegenerative disease treatment (i.e., Alzheimer’s, Parkinson’s, Huntington’s diseases, Amyotrophic Lateral, and Multiple Sclerosis).
View Full-Text
Keywords:
PLGA nanoparticles; neurodegenerative diseases; drug delivery; central nervous system; neuroprotective drugs
▼
Show Figures
Figure 1
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
MDPI and ACS Style
Cunha, A.; Gaubert, A.; Latxague, L.; Dehay, B. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics 2021, 13, 1042. https://doi.org/10.3390/pharmaceutics13071042
AMA Style
Cunha A, Gaubert A, Latxague L, Dehay B. PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases. Pharmaceutics. 2021; 13(7):1042. https://doi.org/10.3390/pharmaceutics13071042
Chicago/Turabian StyleCunha, Anthony, Alexandra Gaubert, Laurent Latxague, and Benjamin Dehay. 2021. "PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases" Pharmaceutics 13, no. 7: 1042. https://doi.org/10.3390/pharmaceutics13071042
Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.
